Reliance Genemedix Limited, a biopharmaceutical company, develops, manufactures, and distributes biotechnology pharmaceuticals. The company’s biosimilars are a generic version of recombinant therapeutic proteins. It is developing EPOSTIM, which is used as a support therapy for the treatment of acute, chronic, and end-stage renal failure; in cancer-induced and chemotherapy related anemia; in patients undergoing major surgeries; and in AIDS patients on zidovudine treatment. The company is headquartered in Tullamore, Ireland. Reliance GeneMedix Limited is a subsidiary of Reliance Life Sciences BV.
IDA Business & Technology Park
Reliance GeneMedix’s AGM Approves Delisting From AIM
Sep 28 12
The board of Reliance GeneMedix plc announceD that at the Annual General Meeting of the Company's shareholders held on September 28, 2012 all resolutions were duly passed including those to cancel the admission to trading on AIM of the Ordinary Shares and to re-register the Company as a private limited company. Consequently, it is expected that the last day of dealings in the Ordinary Shares on AIM will be 5 October 2012 and it is expected that the cancellation of admission to trading on AIM of the Ordinary Shares will take effect from 7.00a.m. (British Summer Time) on 8 October 2012. The earliest date that the Company will be re-registered as a private limited company is expected to be 26 October 2012.
Reliance GeneMedix plc Announces Consolidated Earnings Results for the Year Ended March 31, 2012
Sep 7 12
Reliance GeneMedix plc announced consolidated earnings results for the year ended March 31, 2012. For the year, the company reported loss attributable to equity holders of parent of €2,176,000 or 1.1 cent basic and diluted loss per share on revenue of €615,000 compared to loss attributable to equity holders of parent of €2,931,000 or 1.5 cent basic and diluted loss per share on revenue of €578,000 of prior year. Operating loss was €2,112,000 against €2,137,000 of prior year. Loss before taxation was €2,942,000 against €2,728,000 of prior year. Net cash used in operations was €1,113,000 against €1,860,000 of prior year. Payments for intangible assets were €1,391,000 against €2,615,000 of prior year.
Reliance GeneMedix Proposes to Delist from AIM
Sep 5 12
Reliance GeneMedix plc announced that the Annual General Meeting (AGM) of the Company will be held on September 28, 2012 to consider the proposed cancellation of admission of the Company's Ordinary Shares to trading on AIM. Subject to approval of the de-listing by the requisite majority, it is anticipated that trading of the Ordinary Shares on AIM will cease at the close of business on October 5, 2012 and the effective date of the de-listing will be October 8, 2012.